COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02461771




Registration number
NCT02461771
Ethics application status
Date submitted
2/06/2015
Date registered
3/06/2015
Date last updated
6/10/2020

Titles & IDs
Public title
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Scientific title
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Secondary ID [1] 0 0
POT-CP043014
Universal Trial Number (UTN)
Trial acronym
ASAP II
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neovascular Age-Related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pegcetacoplan

Experimental: Pegcetacoplan Cohort 1 - 4 mg of pegcetacoplan 100 µL IVT injection

Experimental: Pegcetacoplan Cohort 2 - 10 mg of pegcetacoplan 100 µL IVT injection

Experimental: Pegcetacoplan Cohort 3 - 20 mg of pegcetacoplan 100 µL IVT injection


Treatment: Drugs: Pegcetacoplan
On treatment day, subjects will be administered a single 100 µL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity - Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.
Timepoint [1] 0 0
Day 1 to Day 113
Primary outcome [2] 0 0
Number of Dose Limiting Toxicities (DLTs) - The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure =30 millimeters (mm) of mercury, and/or sustained loss of visual acuity =15 letters not attributable to the injection procedure or progression of disease.
Timepoint [2] 0 0
Day 1 to Day 15
Primary outcome [3] 0 0
Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t]) - The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.
Timepoint [3] 0 0
Predose (screening), postdose Day 3 to Day 113
Primary outcome [4] 0 0
Median Dose Normalized AUC(0-t) - The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.
Timepoint [4] 0 0
Predose (screening), postdose Day 3 to Day 113
Primary outcome [5] 0 0
Maximum Observed Serum Concentration (Cmax) - The median Cmax is presented for each cohort.
Timepoint [5] 0 0
Predose (screening), postdose Day 3 to Day 113
Primary outcome [6] 0 0
Median Dose Normalized Cmax - The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.
Timepoint [6] 0 0
Predose (screening), postdose Day 3 to Day 113
Primary outcome [7] 0 0
Median Time to the Maximum Measured Serum Concentration (Tmax) - The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.
Timepoint [7] 0 0
Predose (screening), postdose Day 3 to Day 113
Secondary outcome [1] 0 0
Median Change From Baseline in Visual Acuity for the Study Eye - Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
Timepoint [1] 0 0
Day 1 to Day 113
Secondary outcome [2] 0 0
Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye - Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).
Timepoint [2] 0 0
Day 1 to Day 113
Secondary outcome [3] 0 0
Median Change From Baseline in Macular Cube Volume in the Study Eye - Macular cube volume was determined using SD-OCT.
Timepoint [3] 0 0
Day 1 to Day 113

Eligibility
Key inclusion criteria
1. Male or Female

2. Age = 50 years

3. The presence of an active choroidal neovascular lesion secondary to AMD

4. On treatment with anti-VEGF therapy (Lucentis®, Eylea® or Avastin®)

5. Must have received at least 3 anti-VEGF treatments over the 26-week period prior to
screening (Screening Visit)

6. Evidence that the macular fluid has responded to anti-VEGF in the past based on OCT in
the opinion of PI

7. At screening, evidence of subretinal fluid and retinal cystic changes

8. Must have received anti-VEGF treatment within 10 days prior to pegcetacoplan treatment
(anti-VEGF can be administered on the same day of the screening visit after the
screening procedures have been completed)

9. OCTs of sufficient quality to allow for the assessment of the central macular fluid
can be obtained

10. Female subjects must be:

- Women of non-child-bearing potential (WONCBP), Or

- Women of child-bearing potential (WOCBP) with a negative pregnancy test at
screening and must agree to use protocol defined methods of contraception for the
duration of the study

11. Males with female partners of child-bearing potential must agree to use protocol
defined methods of contraception and agree to refrain from donating sperm for the
duration of the study

12. Willing and able to give informed consent
Minimum age
50 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Choroidal neovascularization associated with other ocular diseases such as pathologic
myopia, ocular histoplasmosis or posterior uveitis, etc

2. Decreased vision due to retinal disease not attributable to choroidal
neovascularization, such as nonexudative forms of AMD, geographic atrophy, inherited
retinal dystrophy, uveitis or epiretinal membrane, a vitelliform-like lesion of the
outer retina (e.g., as in pattern dystrophies or basal laminar drusen), idiopathic
parafoveal telangiectasis, or central serous retinopathy

3. Additional ocular diseases that have irreversibly compromised or, during follow-up,
could likely compromise the VA of the study eye including amblyopia, anterior ischemic
optic neuropathy, clinically significant diabetic macular edema, severe non
proliferative diabetic retinopathy, or proliferative diabetic retinopathy

4. Decreased vision due to significant media opacity such as corneal disease or cataract,
or opacity precluding photography of the retina

5. Cataract surgery within three months of enrollment

6. Presence of any hemorrhage

7. History of treatment for CNV:

1. Previous PDT treatment within 30 days prior to enrollment in the study

2. Previous extrafoveal or juxtafoveal thermal laser photocoagulation within 30 days
prior to enrollment in the study

8. Intraocular surgery (including lens replacement surgery) within 3 months prior to
randomization

9. Medical problems that make consistent follow-up over the treatment period unlikely
(e.g. stroke, severe MI, end stage malignancy), or in general a poor medical risk
because of other systemic diseases or active uncontrolled infections

10. Hypersensitivity to fluorescein

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Australia, New South Wells - Parramatta
Recruitment postcode(s) [1] 0 0
2150 - Parramatta
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
New Hampshire

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Apellis Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this study is to provide initial safety, tolerability and pharmacokinetics
information of intravitreal administration of pegcetacoplan in order to support further
development into larger Phase II studies for treatment of patients with AMD.
Trial website
https://clinicaltrials.gov/show/NCT02461771
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Federico Grossi, MD PhD
Address 0 0
Apellis Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications